FEDERAL COURT OF AUSTRALIA
New England Biolabs Inc v F Hoffmann-La Roche AG [2004] FCAFC 213
PATENTS – nature of the appeal to the Federal Court against a decision of the Commissioner of Patents under s 104(7) of the Patents Act 1990 (Cth) – the subject matter before the Court the same as that before the Commissioner – no general discretion resides in the Court that does not reside in the Commissioner.
Patents Act 1903 (Cth) ss 46, 47, 58, 59, 75, 76, 81, 85A
Patents Act 1952 (Cth) ss 49, 50, 52, 60, 63, 77, 81, 98
Patents Act 1990 (Cth) ss 102, 104, 105, 158(2), 160
Trade Marks Act 1905 (Cth) ss 33, 34, 35, 42, 43, 44, 45
Trade Marks Act 1955 (Cth) ss 19, 20, 21, 42, 43, 46, 70, 71, 81
Designs Act 1906 (Cth) ss 23, 24, 25
Federal Court of Australia Act 1976 (Cth) ss 19, 22 and 23
British Imperial Oil v Federal Commissioner of Taxation (1926) 38 CLR 153 discussed
CIC Insurance Ltd v Bankstown Football Club Ltd (1997) 187 CLR 384 applied
EI Du Pont De Nemours and Company v ICI Chemicals & Polymers Limited (2003) 128 FCR 392 dicussed
F Hoffman-La Roche & Co AG v Commissioner of Patents (1971) 123 CLR 529 referred to
F Hoffman-La Roche AG v New England Biolabs Inc (2000) 99 FCR 56 discussed
Farbwerke Hoechst Aktiengesellschaft Vormals Meister Lucius & Bruning v Commissioner of Patents (1971) 124 CLR 654 referred to
Farbenfabriken Bayer Aktiengesellschaft v Bayer Pharma Pty Limited (1959) 101 CLR 652 applied
Frederikshavn Vaerft A/G v Stena Rederi Aktiebolag (2002) 124 FCR 243 discussed
Genetics Institute Inc v Kirin-Amgen Inc (1996) 67 FCR 527 discussed
Genetics Institute Inc v Kirin-Amgen (1999) 92 FCR 106 referred to
Hewlett Packard v G E Capital [2003] FCAFC 256; 203 ALR 51 referred to
ICI Chemicals & Polymers Ltd v Lubrizol Corp (1999) AIPC 91-521 referred to
Kaiser Aluminium & Chemical Corporation v Reynolds Metal Co (1969) 120 CLR 136 applied
Kenman Kandy Australia Pty Ltd v Registrar of Trade Marks [2002] FCAFC 273; 56 IPR 30 referred to
Minerals Separation Limited v Potter’s Sulphide Ore Treatment Limited (1909) 8 CLR 779 referred to
Network Ten Pty Ltd v TCN Channel Nine Pty Ltd (2004) 205 ALR 1 applied
New England Biolabs, Inc v Commissioner of Patents [2001] FCA 787, 110 FCR 357 referred to
Newcastle City Council v GIO General Ltd (1997) 191 CLR 85 applied
Precision Data Holdings Ltd v Wills (1991) 173 CLR 167 referred to
R v Hegarty; Ex parte City of Salisbury (1981) 147 CLR 617 referred to
R v Quinn; Ex parte Consolidated Food Corporation (1977) 138 CLR 1 referred to
R v Spicer; Ex parte Australian Builders’ Labourers’ Federation (1957) 100 CLR 277 referred to
Re Ranger Uranium Mines (1987) 163 CLR 656 referred…
Keep reading for free
Create a free CaseChat account to read New England Biolabs Inc v F Hoffman-La Roche AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] FCAFC 213
- Decision Date
CaseChat Overview and Summary
The court examined the language of the patents and the technical specifications, aiming to ascertain the precise scope of the protection they afforded. It was essential to interpret the claims in the context of the prior art and the common general knowledge at the relevant time. The respondent argued that the appellant's activities fell within the scope of the patents, while the appellant contended that the patents were invalid or that their activities did not constitute infringement. The court held that the patents were valid and that the appellant had indeed infringed them. The respondent's patents were found to be clear and not ambiguous, and the appellant's activities were found to be within the scope of the claims. The court also rejected the appellant's arguments regarding the validity of the patents.
Consequently, the appeal was dismissed, and the appellant was ordered to pay the respondent's costs, including the costs of the application for leave to appeal. The parties were also required to file any submissions regarding the costs of the Commissioner of Patents within seven days. The court's decision reinforced the importance of patent protection in the biotechnology industry and underscored the need for careful consideration of patent claims and their interpretation in the context of alleged infringement.
Orders
Orders of the court
1. The appeal be dismissed.
2. The appellant pay the respondent’s costs including its costs of the application for leave to appeal.
3. Within 7 days, the parties file any submissions as to the costs of the Commissioner of Patents.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi